Spinal muscular atrophy care in the COVID-19 pandemic era.
SMA
corona
epidemic
guidelines
pandemic
treatment
Journal
Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
16
04
2020
revised:
22
04
2020
accepted:
22
04
2020
pubmed:
25
4
2020
medline:
1
7
2020
entrez:
25
4
2020
Statut:
ppublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic has resulted in reorganization of healthcare settings affecting the delivery of clinical care to patients with spinal muscular atrophy (SMA). There is a concern that patients with SMA may be at increased risk of manifesting severe symptoms of COVID-19. Currently approved therapies for SMA improve survival and motor function; however, their delivery requires an increased exposure to the health system and a dedicated healthcare team. In this study, we discuss consensus recommendations pertaining to care of SMA patients during the pandemic. We highlight that SMA treatments should not be perceived as elective. Decisions regarding the delay of treatments should be made with consideration of the potential risks of COVID-19 exposure and the risk of that delay. We emphasize the importance of collaborative treatment decisions between the patient, family, and healthcare provider, considering any geographic- or institution-specific policies and precautions for COVID-19.
Identifiants
pubmed: 32329921
doi: 10.1002/mus.26903
pmc: PMC7264534
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
46-49Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Muscle Nerve. 2020 Jul;62(1):46-49
pubmed: 32329921
Neuromuscul Disord. 2019 Nov;29(11):842-856
pubmed: 31704158
Infection. 2020 Jun;48(3):445-452
pubmed: 32301099
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-426
pubmed: 32271728
Continuum (Minneap Minn). 2020 Jun;26(3):785-798
pubmed: 32487907
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):411-415
pubmed: 32271722
N Engl J Med. 2020 Mar 26;382(13):1278-1280
pubmed: 32069388
J Clin Pharmacol. 2017 Aug;57(8):1031-1041
pubmed: 28369979
J Med Virol. 2020 Jul;92(7):797-806
pubmed: 32198776
Ther Clin Risk Manag. 2019 Oct 02;15:1153-1161
pubmed: 31632042
J Chin Med Assoc. 2020 Jun;83(6):527-533
pubmed: 32502117
J Clin Virol. 2020 Jun;127:104366
pubmed: 32302954
N Engl J Med. 2018 Feb 15;378(7):625-635
pubmed: 29443664
Expert Opin Pharmacother. 2020 Feb;21(3):307-315
pubmed: 31973611
N Engl J Med. 2017 Nov 2;377(18):1713-1722
pubmed: 29091557
N Engl J Med. 2017 Nov 2;377(18):1723-1732
pubmed: 29091570
Anesth Analg. 2020 Jul;131(1):93-96
pubmed: 32243297